In vivo detection of alzheimer’s disease
(2018) In Yale Journal of Biology and Medicine 91(3). p.291-300- Abstract
Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD†) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches... (More)
Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD†) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches for both the early and accurate identification of AD and as a tool for population enrichment in clinical trials testing candidate disease modifying therapies.
(Less)
- author
- Leuzy, Antoine ; Heurling, Kerstin ; Ashton, Nicholas J. ; Schöll, Michael LU and Zimmer, Eduardo R.
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer’s disease, Diagnosis, Fluid biomarkers, Medical imaging
- in
- Yale Journal of Biology and Medicine
- volume
- 91
- issue
- 3
- pages
- 10 pages
- publisher
- Yale Journal of Biology and Medicine Inc.
- external identifiers
-
- scopus:85054066481
- pmid:30258316
- ISSN
- 0044-0086
- language
- English
- LU publication?
- yes
- id
- e23c3653-2c8c-42d5-ab5a-2183e66f546a
- alternative location
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153625/
- date added to LUP
- 2018-10-15 14:23:29
- date last changed
- 2024-04-15 15:10:48
@article{e23c3653-2c8c-42d5-ab5a-2183e66f546a,
abstract = {{<p>Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD†) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches for both the early and accurate identification of AD and as a tool for population enrichment in clinical trials testing candidate disease modifying therapies.</p>}},
author = {{Leuzy, Antoine and Heurling, Kerstin and Ashton, Nicholas J. and Schöll, Michael and Zimmer, Eduardo R.}},
issn = {{0044-0086}},
keywords = {{Alzheimer’s disease; Diagnosis; Fluid biomarkers; Medical imaging}},
language = {{eng}},
number = {{3}},
pages = {{291--300}},
publisher = {{Yale Journal of Biology and Medicine Inc.}},
series = {{Yale Journal of Biology and Medicine}},
title = {{In vivo detection of alzheimer’s disease}},
url = {{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153625/}},
volume = {{91}},
year = {{2018}},
}